期刊文献+

慢性乙型肝炎患者外周血单个核细胞中趋化因子IP-10和Mig表达及其与干扰素治疗的相互关系 被引量:13

The influence of IFN on expression of chemokines IP-10,Mig in the patients with chronic hepatitis B
原文传递
导出
摘要 目的探讨慢性乙型肝炎患者外周血单个核细胞(PBMC)中部分CXC趋化因子(IP-10、Mig)mRNA表达水平,并比较2种类型干扰素-α(IFN-α)联合利巴韦林治疗后对其表达水平的影响。方法对2004年1月至2005年6月淮南第二矿工医院感染科收治的45例慢性乙型肝炎患者以实时聚合酶链反应(Real-timePCR)法动态检测其经IFN-α联合利巴韦林治疗前、治疗3个月、6个月后PBMC内IP-10、MigmRNA的含量,同时选取同期24例体检正常献血员为对照组,测量其PBMC内IP-10、MigmRNA的含量。2组均以趋化因子与管家基因GAPDH的对数比值为其最终相对表达量。结果慢性乙型肝炎患者治疗前IP-10、MigmRNA表达水平分别为(0.7387±0.0768)、(0.6883±0.0693),显著高于对照组(P<0.001)。IFN-α治疗3个月后IP-10、MigmRNA表达水平分别为(0.5741±0.0912)、(0.5962±0.0987),与治疗前相比,差异有显著性(P<0.05~P<0.001)。IFN-α治疗6个月后IP-10、MigmRNA表达水平分别为(0.4235±0.0924)、(0.4105±0.0898),与治疗前相比,差异有显著性(P<0.001)。普通IFN-α和聚乙二醇化干扰素-α(PEG-IFN-α)治疗后各趋化因子表达水平不同,差异有显著性(P<0.05~P<0.001)。结论慢性乙型肝炎患者PBMC中IP-10、MigmRNA表达升高,普通IFN-α和PEG-IFN-α均能显著下调IP-10、MigmRNA表达水平,PEG-IFN-α治疗组疗效优于普通IFN-α组。IFN这种免疫调节作用,对降低患者体内炎性反应、控制病情发展十分有利。 Objective To study the levels of some CXC chemokines mRNA in patients with chronic hepatitis B and its changes after combinative treatment of two types interferon-α (IFN-α) with Ribavirin. The logarithm rate of chemokine/ GAPDH was regarded as the extreme level of chemokine, Methods The different levels of IP-10 and Mig mRNA in peripheral blood mononuclear cells (PBMC)of chronic hepatitis B were kinetically detected by real-time polymerase chain reaction(real-time PCR)in different treatment stages, Results The expression levels of IP-10 and Mig mRNA in peripheral blood of patients were(0.7387 ± 0.0768 ), (0. 6883 ± 0.0693 ), respectively, Which were significantly higher than that in normal controls( P 〈 0, 001 ), After treatment for three months ,the expressive levels of IP-10 and Mig mRNA were (0. 5741 ± 0. 0912), (0. 5962 ± 0, 0987 ), respectively. There was significant difference between before treatment "and after treatment( P 〈 0. 05 - P 〈 0. 001 ). After treatment for six months, the expressive levels of IP-10 and Mig mRNA were (0.4235±0.0924), (0.4105 ± 0. 0898 ), respectively, There was higher significant difference between before treatment and after treatment(P 〈 0. 001 ), There was difference for the expression of ehemokines between the general IFN-α and PEG-IFN-α (P 〈 0. 05- P 〈 0, 001 ). Conclusion This study shows that the expression of IP-10 and Mig mRNA are high in patients with chronic hepatitis B, Both the general IFN-α and PEG-IFN-α can conspicuously down-regulate the levels of IP-10 and Mig mRNA to adjacent normal level in patients with chronic hepatitis B. The curative effect of PEG-IFN-α group is better than that of IFN-α group. IFN-α plays an important role in down-regulating inflammation response, controlling the development of the patients' condition.
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2007年第4期285-288,共4页 Chinese Journal of Practical Internal Medicine
基金 安徽省教育厅自然科学基金(2003kj027zd)
关键词 乙型肝炎 趋化因子 干扰素-Α Hepatitis B Chemokine Interferon-α
  • 相关文献

参考文献14

  • 1Guidotti LG, Morris A, Mendez H, et al. Interferon-regulated pathways that control hepatitis B virus replication in transgenic mice [J]. J Virol,2002,76(6) :2617 -2621.
  • 2Fujiie S, Hieshima K, Izawa D, et al. Proinflammatory eytokines induce liver and activation-regulated chemokine/macrophage inflammatory protein-3alpha/CCL20 in mucosal epithelial cells through NF-kappaB[ J]. Int Immunol,2001,13(10) :1255 - 1263.
  • 3Apolinario A, Majano PL, Lorente R, et al. Gene expression profile of T-cell-specific chemokines in human hepatocyte-derived cells:evidence for a synergistic inducer effect of cytokines and hepatitis C virus proteins[J]. J Viral Hepat,2005,12( 1 ) :27 -37.
  • 4Laing KJ, Secombes CJ. Chemokines [ J ]. Dev Comp Immunol,2004,28(5 ) :443 -460.
  • 5Salazar-Mather TP, Hamilton TA, Biron CA. A ehemokine-to-cytokine-to-chemokine cascade critical in antiviral defense[ J ]. J Clin Invest ,2000,105 (7) :985 - 993.
  • 6Kakimi K,Lane TE,Wieland S,et al. Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes [ J ]. J Exp Med, 2001,194 ( 12 ) : 1755 -1766.
  • 7Bieche I, Asselah T, Laurendeau I, et al. Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection [ J ]. Virology,2005,332 ( 1 ) : 130 - 144.
  • 8Mihm S, Schweyer S, Ramadori G. Expression of the chemokine IP-10 correlates with the accumulation of hepatic IFN-gamma and IL-18 mRNA in chronic hepatitis C but not in hepatitis B[J]. J Med Virol,2003,70(4 ) :562 - 570.
  • 9赵国明,俞红,张红薇,周霞秋.干扰素α-2b治疗慢性乙型肝炎近期疗效分析[J].中国实用内科杂志,2004,24(6):361-362. 被引量:6
  • 10Sypsa VA, Mimidis K,Tassopoulos NC, et al. A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative [ J ]. Hepatology,2005,42(1) :77 -85.

二级参考文献44

  • 1[3]Lok ASF,Heathente EJ,Hoofnagle JH.Management of hepatitis B 2000:summary of a workshop.Gastroenterology,2001,120(7):1828-1853
  • 2[4]Yuen MF,Hui CK,Cheng CC,et al.Long-term follow-up patients with chronic hepatitis B infection:the effect on hepatitis B e-antigen seroconversion and the development of cirrhosis-related complications.Hepatology,2001,34(1):139-145
  • 3[5]Perrllo RP.Acute flares in chronic hepatitis B:the natural and unnatural history of an immunologyically mediated infection.Gastroenterology,2001,120(4):1009-1022
  • 4Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med, 1992, 327: 1899-1905.
  • 5Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med, 2002, 347: 975-982.
  • 6Fanning LJ, Kenny-Walsh E, Shanahan F. Persistence of hepatitis C virus in a white population: associations with human leukocyte antigen class 1. Hum Immunol, 2004, 659: 745-751.
  • 7McKiernan SM, Hagan R, Curry M, et al. Distinct MHC class Ⅰ and Ⅱ alleles are associated with hepatitis C viral clearance, originating from a single source. Hepatology, 2004, 40: 108-114.
  • 8Barrett S, Collins M, Kenny C, et al. Polymorphisms in tumour necrosis actor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection. J Med Virol, 2003, 71: 212-218.
  • 9Konishi I, Horiike N, Hiasa Y, et al. CCR5 promoter polymorphism influences the interferon response of patients with chronic hepatitis C in Japan. Intervirology, 2004, 47: 114-120.
  • 10Hellier S, Frodsham AJ, Hennig BJ, et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology, 2003, 38: 1468-1476.

共引文献15

同被引文献98

引证文献13

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部